Evaluating vibegron for the treatment of overactive bladder

References

• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–1138.
   PubMed Web of Science ®Google Scholar
• Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn. 2010;29:408–412.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Vibegron: first global approval. Drugs. 2018;78(17):1835–1839.
   PubMed Web of Science ®Google Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74:324–333.
   PubMed Web of Science ®Google Scholar
• Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62:1165–1173.
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448.
   PubMed Web of Science ®Google Scholar
• Di Salvo J, Nagabukuro H, Wickham LA, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther. 2017;360(2):346–355.
   PubMed Web of Science ®Google Scholar
• Kyorin Pharmaceutical. Beova tablets 50 mg: Japanese prescribing information. 2018 [cited 2020 Apr 04]. Available from: www.kyorin-gr.co.jp/en/news/docs/57a20666168a4c90f3519957b2d2f928028651b5.pdf
   Google Scholar
• Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–623.
   PubMed Web of Science ®Google Scholar
• Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, Phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019 Feb;75(2):274–282. Epub 2018 Oct 25.
   PubMed Web of Science ®Google Scholar
• Rutman MP, King JR, Bennett N, et al. Once-daily vibegron, a novel oral β3 agonist does not inhibit CYP2D6, a common pathway drug metabolism in patients on OAB. J Urol. 2019;201(4S):PD14–01.
   Google Scholar
• Limberg BJ, Andersson KE, Aura Kullmann F, et al. β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010;342:295–306.
   PubMed Web of Science ®Google Scholar
• Nagabukuro H, Villa KL, Wickham LA, et al. Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents. J Pharmacol Exp Ther. 2011;338:220–227.
   PubMed Web of Science ®Google Scholar
• Bordicchia M, Pocognoli A, D’Anzeo M, et al. Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes. J Hypertens. 2014;32:389–396.
   PubMed Web of Science ®Google Scholar
• Ursino MG, Vasina V, Raschi E, et al. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res. 2009;59:221–s34.
   PubMed Web of Science ®Google Scholar
• Matsui M, Griffin MT, Shehnaz D, et al. Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice. J Pharmacol Exp Ther. 2003;305:106–113.
   PubMed Web of Science ®Google Scholar
• Ehlert FJ, Ahn S, Pak KJ, et al. Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder. J Pharmacol Exp Ther. 2007;322:631–637.
   PubMed Web of Science ®Google Scholar
• Furuta A, Suzuki Y, Kimura S, et al. Combination therapy with β3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: efficacy in rats with bladder overactivity. Int J Urol. 2016;23:425–430.
   PubMed Web of Science ®Google Scholar
• Masunaga K, Chapple CR, McKay NG, et al. The β3 adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome. Neurourol Urodyn. 2010;29:1320–1325.
   PubMed Web of Science ®Google Scholar
• Kullmann FA, Downs TR, Artim DE, et al. Urothelial beta-3 adrenergic receptors in the rat bladder. Neurourol Urodyn. 2011;30:144–150.
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:473–481.
   PubMed Web of Science ®Google Scholar
• Propping S, Wuest M, Eichhorn B, et al. Mucosa of human detrusor impairs contraction and b-adrenoceptor-mediated relaxation. BJU Int. 2013;112:1215–1222.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Maruyama I. Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats. Eur J Pharmacol. 2019 Dec;1(864):172727.
   Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577–588.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Mitcheson D, Frenkl T, et al. Durable efficacy and safety of long-term once-daily vibegron, a novel oral β-3 adrenergic receptor agonist: a 52-week phase 2 study in patients with overactive bladder syndrome [abstract no. PD50-03]. J Urol. 2018;199(4Suppl):e970–e1.
   Google Scholar
• Yoshida M, Kakizaki H, Takahashi S, et al. Long-term safety and efficacy of the novel beta3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study. Int J Urol. 2018;25(7):668–675.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective bea3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783–790.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020 Jan 28;125(5):709–717. published online.
   PubMed Web of Science ®Google Scholar
• Staskin D, Frankel J, Varano S, et al. International Phase III, randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020 Feb;204:316–324. published online.
   Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol. 2019 Mar;26(3):369–375.
   PubMed Web of Science ®Google Scholar
• Homma Y, Yamaguchi O; Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with over- active bladder. Int J Urol. 2009;16:499–506.
   PubMed Web of Science ®Google Scholar
• Anthony A, Schepelmann S, Guillaume L, et al. Localization of the b(beta) 3 -adrenoceptor in the human gastrointestinal tract: an immunohistochemical study. Aliment Pharmacol Ther. 1998;12:519–525.
   PubMed Web of Science ®Google Scholar
• Fox C, Livingston G, Maidment ID, et al. The impact of anticholinergic burden in Alzheimer’s dementia-the LASER-AD study. Age Ageing. 2011 Nov;40(6):730–735.
   PubMed Web of Science ®Google Scholar
• Sink KM, Thomas J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008 May;56(5):847–853.
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar;175(3):401–407.
   PubMed Web of Science ®Google Scholar
• Caremel R, Loutochin O, Corcos J. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? Int Urogynecol J. 2014;25(2):165–170.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Carillon C, Coquerel A, et al. Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Brain Res Mol Brain Res. 1995;29:369–375.
   PubMedGoogle Scholar
• Bragg R, Hebel D, Vouri SM, et al. Mirabegron: a beta-3 agonist for overactive bladder. Consult Pharm. 2014;29:823–837.
   PubMedGoogle Scholar
• Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7:204–216.
   PubMed Web of Science ®Google Scholar